Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

The purpose of this study is to evaluate the efficacy and safety of avapritinib in relapsed or refractory pediatric core binding factor acute myeloid leukemia with KIT mutation.

Trial Details

NCT ID
NCT06316960
Phase
PHASE2
Sponsor
Children's Hospital of Soochow University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Avapritinib
  • Azacitidine Injection
  • Decitabine Injection
  • Idarubicin Hydrochloride
  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
Locations (sample)
  • Hefei, Anhui, China|31.86389,117.28083
  • Hefei, Anhui, China|31.86389,117.28083
  • Guangzhou, Guangdong, China|23.11667,113.25
  • Nanning, Guangxi, China|22.81667,108.31667
  • Kaifeng, Henan, China|34.7986,114.30742

Key Eligibility Criteria

  • Gender unlimited;
  • Under 18 years;
  • Diagnosis of acute myeloid leukemia (according to the 2022 WHO classification).
  • Presence of t(8;21)/RUNX1::RUNX1T1 or inv(16)/t(16;16)/CBFβ::MYH11;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →